1 / 7

Community acquired pneumonia and treatment options

CAP patient characteristics. Smokers: S. pneumo, H. influenzae, MoraxellaPost viral bronchitis: S. pneumoNo co-morbidity: atypicals, viralAlcoholic: S. pneumo, anaerobesIV drug user: S. aureusEpidemic: Legionnaire'sAirway obstruction: anaerobesAnimals: Psittacosis, Tularemia, Coxiella burneti

leigh
Download Presentation

Community acquired pneumonia and treatment options

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    1. Community acquired pneumonia and treatment options 6 mechanisms in pathogenesis of pneumonia – (inhalation, aspiration, direct inoculation, reactivation, defects in pulmonary defenses, blunted cellular or humoral immune response) In general, clinical presentation: pleuritic chest pain, fever, cough, decreased breath sounds, dull to percussion, egophony Classified as “typical” or “atypical” or viral Typical = S. pneumoniae, H. influenza, S. aureus, enteric gram negative bacteria. More segmental or lobar infiltrate. Atypical = Mycoplasma, Legionella, Chlamydia pneumonia. More diffuse infiltrate. Sputum gram stain usually negative. Empiric treatment prior to susceptibility testing- cover S. pneumoniae, S. aureus, H. influenzae. Give amoxicillin-clavulanate, and 2nd or 3rd generation cephalosporin, or respiratory fluoroquinolone (3rd and 4th generation).

    2. CAP patient characteristics Smokers: S. pneumo, H. influenzae, Moraxella Post viral bronchitis: S. pneumo No co-morbidity: atypicals, viral Alcoholic: S. pneumo, anaerobes IV drug user: S. aureus Epidemic: Legionnaire’s Airway obstruction: anaerobes Animals: Psittacosis, Tularemia, Coxiella burnetii

    3. Mechanisms of action of different antimicrobials Penicillins- Inhibits the transpeptidase enzyme step in peptidoglycan cell wall synthesis 1st generation:[ex Pen G] most streptococci, oral anaerobic coverage 2nd generation:[nafcillin] most streptococci, S. aureus (Penicillinase resistant) 3rd generation:[amoxicillin, ampicillin] most streptococci, basic G – coverage. Amoxicillin is oral DOC for susceptible strains of S. pneumoniae Amoxicillin with clavulanate treats beta lactamase producing bacteria like H. influenzae, Methicillin sensitive Staph aureus and anaerobes 4th generation:[piperacillin] extended spectrum, includes pseudomonas Cephalosporins-inhibits cell wall synthesis Parenteral DOC for CAP caused by susceptible strains of S pneumoniae, H influenzae, Staph aureus. 1st generation: G+ (including Staph aureus), basic G- 2nd generation: G+, diminished Staph aureus, improved G- coverage, some anaerobic coverage 3rd generation: further diminished S. aureus, further improved G-, some Pseudomonal coverage and diminished G+ coverage 4th generation: same as 3rd plus coverage against Pseudomonas **note that neither group is effective against “atypicals”

    4. Macroglides-inhibits 50s subunit of ribosome in protein synthesis Treats mycoplasma, legionnaire’s, chlamydial infections Active against most common pathogens and atypical agents. Macroglide resistance is emerging to Strep pneumoniae Fluoroquinolones-inhibits DNA gyrase Broad spectrum against likely agents of CAP. Active against penicillin resistant Strep pneumoniae. Resistance developing. 1st generation: G- NOT pseudomonas, UTI only, NO atypicals 2nd generation: G- including pseudomonas, S. aureus, some atypicals NOT pneumococcus 3rd generation: G-, G+, expanded atypicals 4th generation: same as 3rd plus enhanced coverage of pneumococcus, decreased activity vs pseudomonas. Tetracyclines- inhibits 30s subunit of ribosome in protein synthesis G+ and G-, aerobic & anaerobic bacteria, “atypicals”- mycoplasma, chlamydia and category A bioterrorism agents

    5. Streptococcus pneumoniae (2/3 of CAP cases) Properties: G + diplococci “lancet shaped”, a hemolytic. #1 cause CAP: “rusty sputum”, single rigor, fever. Tx and dose: sensitive strains treat with penicillin G 250,000-400,000 units/kg/day IV divided q 4-6 or amoxicillin (oral) 1g PO tid. intermediate resistance strains are susceptible to 2nd/3rd generation parenteral cephalosporins and respiratory fluoroquinolones Cefotaxime 1-2g IM/IV q6-8 or ceftriaxone1-2 g IM/IV q24h. Levofloxicin 500mgIV/po qd (others: alatrofox-, gati-, moxi-) Prevention: capsular vaccines (prevnar, pneumovax)

    6. H. influenzae trimethoprim-sulfamethoxazole, Ampicillin IV, Amoxicillin po, azithro/clarithromycin, doxycycline If severe, 3rd gen cephalosporin Enteric gram negatives Anaerobes: clindamycin or beta lactam/beta lactamase inhibitor Staph aureus Sensitive strains: Nafcillin or oxacillin (penicillinase resistant abx) MRSA- Vancomycin Atypicals Legionella- fluroquinolone or azithromycin Mycoplasma- erythro, azithro, clarithromycin, or fluoroquinolone Chlamydia pneumoniae- doxycycline, erythrocyclin or floroquinolones

    7. Duration of therapy S pneumoniae: until afebrile for 3-5d C pneumoniae:7-14 d M pneumoniae: not well established. Legionella: 10-21 d S aureus, P aeruginosa, Klebsiella, anaerobes >3weeks

More Related